NEW YORK (GenomeWeb) – A pair of studies has linked gene amplifications on chromosome 14 to drug resistance among malaria parasites.

Some 200 million people are infected and half a million die each year from malaria. In Southeast Asia, first-line treatment for malaria is typically a combination therapy of artemisinin and piperaquine. While resistance to artemisinin began to emerge there more than seven years ago, resistance to piperaquine in the malaria-causing parasite Plasmodium falciparum has developed more recently.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Sponsored by

This webinar will discuss how new quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) tests can accelerate the discovery and development of much-needed anti-malarial drugs and vaccines.